Signal
Two new cancer cases have prompted Kyowa Kirin to shutter all studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory dis...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-03-03 16:17 UTCUpdated 2026-03-03 17:22 UTC
rss
biopharma_dive
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Coverage centers on: Kyowa Kirin abandons touted eczema drug following safety review.
Score total
0.97
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Kyowa Kirin abandons touted eczema drug following safety review
BioPharma Dive · biopharmadive.com · 2026-03-03 17:22 UTC
Two new cancer cases have prompted Kyowa Kirin to shutter all studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory diseases.
Fierce Biotech · fiercebiotech.com · 2026-03-03 16:17 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)